Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Atea Pharmaceuticals Inc

AVIR
Current price
3.65 USD -0.07 USD (-1.88%)
Last closed 3.7 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 327 627 872 USD
Yield for 12 month -1.35 %
1Y
3Y
5Y
10Y
15Y
AVIR
21.11.2021 - 28.11.2021

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.5 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+192 180 000 USD

Current Quarter

Last Quarter

Current Year

-416 000 USD

Last Year

-260 000 USD

Current Quarter

-104 000 USD

Last Quarter

-104 000 USD

Key Figures AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -119 593 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -11.89 %
PEG Ratio
Return On Equity TTM -22.74 %
Wall Street Target Price 3.5 USD
Revenue TTM 192 180 000 USD
Book Value 6.65 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 295.2 %
Dividend Yield
Gross Profit TTM -81 936 000 USD
Earnings per share -1.63 USD
Diluted Eps TTM -1.63 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY 264.1 %
Profit Margin

Dividend Analytics AVIR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AVIR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 58.974
Price Sales TTM 1.9026
Enterprise Value EBITDA 1.5832
Price Book MRQ 0.57

Financials AVIR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AVIR

For 52 weeks

2.77 USD 5.19 USD
50 Day MA 3.89 USD
Shares Short Prior Month 1 747 450
200 Day MA 3.48 USD
Short Ratio 8.67
Shares Short 1 798 410
Short Percent 3 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

420.21 USD Microsoft Corporation -1.96 (-0.46%)
Detailed analytics

ETF funds


S

SX7EEX

14.76 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) +0.03 (+0.2%)
Detailed analytics

Metals


Gold

2414.65 USD Gold +37.17 (+1.56%)
Detailed analytics